# Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

> **NCT04606784** · PHASE1 · COMPLETED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 40 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Ampion
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04606784
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-28
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04606784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04606784, "Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04606784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*